{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+-+Part+1&page=7",
    "query": {
      "intervention": "Treatment C - Part 1",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 541,
    "total_pages": 55,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+-+Part+1&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+C+-+Part+1&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T12:54:58.136Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03847519",
      "title": "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell",
        "Metastatic Squamous Cell Carcinoma",
        "Metastatic Non-Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADXS-503",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advaxis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-02-12",
      "completion_date": "2022-02-22",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03847519"
    },
    {
      "nct_id": "NCT03276728",
      "title": "Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Failure",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "AMG 986 IV",
          "type": "DRUG"
        },
        {
          "name": "AMG 986 PO",
          "type": "DRUG"
        },
        {
          "name": "Placebo PO",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 182,
      "start_date": "2016-08-12",
      "completion_date": "2019-04-18",
      "has_results": true,
      "last_update_posted_date": "2022-08-08",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03276728"
    },
    {
      "nct_id": "NCT05867420",
      "title": "A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ASKG915",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel + Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AskGene Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 594,
      "start_date": "2023-08-02",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 2,
      "location_summary": "New York, New York • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05867420"
    },
    {
      "nct_id": "NCT05279755",
      "title": "A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "prosetin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ProJenX",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-02-26",
      "completion_date": "2026-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • San Antonio, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05279755"
    },
    {
      "nct_id": "NCT03633617",
      "title": "Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 321,
      "start_date": "2018-09-24",
      "completion_date": "2022-06-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 62,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03633617"
    },
    {
      "nct_id": "NCT04669587",
      "title": "ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-Positive",
        "HER2-Negative",
        "Locally Advanced Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ZB716",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EnhancedBio USA Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2021-07-26",
      "completion_date": "2024-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-03-22",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04669587"
    },
    {
      "nct_id": "NCT03078556",
      "title": "Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 154,
      "start_date": "2017-03-27",
      "completion_date": "2017-08-18",
      "has_results": true,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078556"
    },
    {
      "nct_id": "NCT01045863",
      "title": "To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-03382792 Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "PF-03382792 Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "PF-03382792",
          "type": "DRUG"
        },
        {
          "name": "Food Effect cohort",
          "type": "DRUG"
        },
        {
          "name": "CSF cohort",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2010-02",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2010-08-04",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01045863"
    },
    {
      "nct_id": "NCT04990440",
      "title": "A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "Bermekimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2021-09-02",
      "completion_date": "2022-03-09",
      "has_results": true,
      "last_update_posted_date": "2023-05-24",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 6,
      "location_summary": "Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chesterfield",
          "state": "Michigan"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04990440"
    },
    {
      "nct_id": "NCT05280717",
      "title": "Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "sotrovimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 316,
      "start_date": "2022-03-28",
      "completion_date": "2023-11-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-09T12:54:58.136Z",
      "location_count": 10,
      "location_summary": "Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Binghamton",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05280717"
    }
  ]
}